english.prescrire.org > Prescrire International > N°162 - July 2015

n°162

July 2015

Issue Contents
Editorial

Free  Lifting the veil

p.172
French regulators in the hot seat

Marketing Authorisations


Propranolol (Hemangiol°) and severe infantile haemangiomas

p.173-176
The drug of first choice

Lomitapide (Lojuxta°)

p.176-178
Use only in homozygous familial hypercholesterolaemia, with caution

Vedolizumab (Entyvio°)

p.178-179
No proven advantage in Crohn's disease or ulcerative colitis

INN common stem: -tapide

p.179

Adverse Effects


Drug-induced urinary incontinence

p.180-182
Significant impact on patients' quality of life

Urinary continence and incontinence, in brief

p.181

Misoprostol: serious cardiovascular events, even after a single dose

p.183-184
High-risk situations should be identified

Pharmacology of prostaglandins, in brief

p.184

Drugs for hypotension: disproportionate harms with etilefrine and heptaminol

p.184
Market withdrawal is required

Free  Cotrimoxazole + an ACE inhibitor or ARB: sudden death

p.185
Hyperkalaemia

Free  Galantamine: serious skin reactions

p.185
A decidedly bad drug

Free  Topiramate: visual field defects

p.185
Regular warning is needed

Free  Cotrimoxazole: fatal thrombocytopenia

p.185
Hypersensitivity

Reviews


Mammographic screening for breast cancer

p.186-191
Overdiagnosis: an insidious adverse effect of screening

Other adverse effects of screening mammography

p.189

Sharing relevant information with women to help them decide whether or not to participate in breast cancer screening

p.190
Prescrire's advice

Hydroxyzine: choose other treatments

p.191
No role in therapeutics

Outlook


Free  New drug pricing: does it make any sense?

p.192-195
A presentation by Marc-André Gagnon, Assistant Professor in public policy at Carleton University (Ottawa, Canada)

Masthead


Free  Masthead

p.170

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe